Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Her-2 DNA versus cell vaccine: immunogenicity and anti-tumor activity.
Whittington PJ, Radkevich-Brown O, Jacob JB, Jones RF, Weise AM, Wei WZ. Whittington PJ, et al. Among authors: weise am. Cancer Immunol Immunother. 2009 May;58(5):759-67. doi: 10.1007/s00262-008-0599-x. Epub 2008 Oct 3. Cancer Immunol Immunother. 2009. PMID: 18836716 Free PMC article.
Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination.
Gibson HM, Veenstra JJ, Jones R, Vaishampayan U, Sauerbrey M, Bepler G, Lum L, Reyes J, Weise A, Wei WZ. Gibson HM, et al. Cancer Immunol Res. 2015 Jul;3(7):777-86. doi: 10.1158/2326-6066.CIR-14-0175. Epub 2015 Feb 23. Cancer Immunol Res. 2015. PMID: 25711535 Free PMC article.
Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies.
Naing A, Infante J, Goel S, Burris H, Black C, Marshall S, Achour I, Barbee S, May R, Morehouse C, Pollizzi K, Song X, Steele K, Elgeioushi N, Walcott F, Karakunnel J, LoRusso P, Weise A, Eder J, Curti B, Oberst M. Naing A, et al. J Immunother Cancer. 2019 Aug 22;7(1):225. doi: 10.1186/s40425-019-0665-2. J Immunother Cancer. 2019. PMID: 31439037 Free PMC article. Clinical Trial.
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.
Sanborn RE, Pishvaian MJ, Callahan MK, Weise A, Sikic BI, Rahma O, Cho DC, Rizvi NA, Sznol M, Lutzky J, Bauman JE, Bitting RL, Starodub A, Jimeno A, Reardon DA, Kaley T, Iwamoto F, Baehring JM, Subramaniam DS, Aragon-Ching JB, Hawthorne TR, Rawls T, Yellin M, Keler T. Sanborn RE, et al. J Immunother Cancer. 2022 Aug;10(8):e005147. doi: 10.1136/jitc-2022-005147. J Immunother Cancer. 2022. PMID: 35940825 Free PMC article.
First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors.
Garrido-Laguna I, Krop I, Burris HA 3rd, Hamilton E, Braiteh F, Weise AM, Abu-Khalaf M, Werner TL, Pirie-Shepherd S, Zopf CJ, Lakshminarayanan M, Holland JS, Baffa R, Hong DS. Garrido-Laguna I, et al. Among authors: weise am. Int J Cancer. 2019 Oct 1;145(7):1798-1808. doi: 10.1002/ijc.32154. Epub 2019 Feb 23. Int J Cancer. 2019. PMID: 30680712 Free PMC article. Clinical Trial.
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma.
Shapiro GI, LoRusso P, Dowlati A, T Do K, Jacobson CA, Vaishampayan U, Weise A, Caimi PF, Eder JP, French CA, Labriola-Tompkins E, Boisserie F, Pierceall WE, Zhi J, Passe S, DeMario M, Kornacker M, Armand P. Shapiro GI, et al. Br J Cancer. 2021 Feb;124(4):744-753. doi: 10.1038/s41416-020-01180-1. Epub 2020 Dec 14. Br J Cancer. 2021. PMID: 33311588 Free PMC article. Clinical Trial.
33 results